Physician profile
Ryan Edward Baker
NPI 1992077069
$2,202.90
in general payments reported to CMS, 2019-2025
27 companies · $717 in 2025
The $717 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $277 · 2022: $367 · 2023: $425 · 2024: $418 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,559.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $275.14 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Intra-Sana Laboratories | $263.43 | 2023-2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Exact Sciences Corporation | $242.35 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $200.60 | 2021-2025 | Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $148.04 | 2022-2025 | |
| Abbvie INC. | $143.61 | 2021-2025 | |
| Novo Nordisk INC | $108.00 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Medtronic, INC. | $95.73 | 2021-2023 | Minimed 780g |
| Baxter Healthcare | $87.99 | 2022 | |
| Novartis Pharmaceuticals Corporation | $82.04 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $75.59 | 2021-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Takeda Pharmaceuticals U.S.A., INC. | $62.83 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.46 | 2021-2024 | Cycloset, Xifaxan |
| Janssen Pharmaceuticals, INC | $51.36 | 2021-2023 | Xarelto |
| Dexcom, INC. | $37.89 | 2025 | Dexcom G6 Transmitter |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $34.76 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $31.73 | 2022 | |
| Genzyme Corporation | $27.07 | 2025 | |
| Sumitomo Pharma America, INC. | $26.96 | 2024 | Gemtesa |
| Esperion Therapeutics, INC. | $24.33 | 2021 | |
| Renalytix Ai, INC. | $23.41 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Boston Scientific Corporation | $21.31 | 2022 | |
| Global Blood Therapeutics, INC. | $20.21 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.43 | 2022 | |
| Amgen INC. | $17.91 | 2025 | Repatha, Otezla |
| Currax Pharmaceuticals LLC | $16.64 | 2022 | |
| Shield Therapeutics INC | $13.08 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.